Michael Forbes, CEO of Adastra, mentioned in his initial push release: “Harm reduction is actually a critically critical and mainstream topic, and we have been remaining in the forefront of drug regulations through the board.” May possibly offer substandard and falsified remedies built or distributed under unregulated and most likely unsafe